Honest Criticisms and Limitations of the LEADER Trial
A deep-dive into the enrollment biases, statistical caveats, generalizability gaps, and conflict-of-interest concerns raised about the LEADER cardiovascular outcomes trial for liraglutide.
Trials Leader
8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
8articles
3topic areas covered
May 25, 2026latest review
Trials Leader library
Showing 8 of 8 clinical reviews.
Inside the LEADER Methodology: What Most Summaries Skip
A deep dive into the LEADER trial's randomization, blinding, endpoint adjudication, statistical design, and how each methodological choice shapes interpretation of liraglutide's 13% MACE reduction in type 2 diabetes.
LEADER Extension Data and What Happened After the Trial Ended
Deep-dive into post-trial follow-up from the LEADER cardiovascular outcomes trial of liraglutide in type 2 diabetes, covering durability of MACE reduction, late safety signals, and long-term clinical implications.
LEADER Results in Detail: Numbers, Subgroups, and Time Course
A detailed breakdown of the LEADER trial's primary MACE endpoint, secondary outcomes, time-course analysis, and subgroup responses for liraglutide in type 2 diabetes with high cardiovascular risk.
LEADER Subgroup Analyses: Who Responded Most and Least
A detailed breakdown of the LEADER trial's pre-specified and post-hoc subgroup analyses, examining how liraglutide's cardiovascular benefit varied by age, sex, BMI, baseline biomarkers, and race/ethnicity in patients with type 2 diabetes.
LEADER Trial Cost-Effectiveness: Is Liraglutide Worth the Price for Cardiovascular Protection?
Health-economic analyses from the LEADER trial examined whether liraglutide's 13% MACE reduction in high-risk type 2 diabetes justifies its cost per QALY gained, with implications for payer coverage and patient decision-making.
LEADER Trial: A Plain-English Overview of What It Established
A deep-dive overview of the LEADER trial, the first GLP-1 receptor agonist cardiovascular outcomes trial to show a significant reduction in major adverse cardiovascular events in adults with type 2 diabetes and high cardiovascular risk.
What LEADER Actually Changes in Clinical Practice
How the LEADER trial's 13% MACE reduction with liraglutide reshaped guideline recommendations, prescribing hierarchies, and GLP-1 receptor agonist use in type 2 diabetes with cardiovascular risk.